SCHEMBL21852916

SCHEMBL21852916

Clc1ncc(-c2ccncc2)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.55
LMNA P02545 1/20 0.55
PDGFRB P09619 5/20 0.48
PDGFRA P16234 5/20 0.48
NOTUM Q6P988 1/20 0.46
DYRK1A Q13627 1/20 0.42
PIK3CD O00329 2/20 0.42
PIK3CA P42336 2/20 0.42
PIK3CB P42338 2/20 0.42
PIK3CG P48736 2/20 0.42
EGFR P00533 1/20 0.41
KDR P35968 2/20 0.41
AURKA O14965 1/20 0.40
TTK P33981 1/20 0.40
AURKB Q96GD4 1/20 0.40
INCENP Q9NQS7 1/20 0.40
FLT1 P17948 1/20 0.40
FLT4 P35916 1/20 0.40
KIF11 P52732 2/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8098714 0.81 NPC1 (0.35) MAPTPIK3CDKDM4ESMN1; SMN2
SCHEMBL27844418 0.78 MAPT (0.92) MAPTLMNANOTUMKIF11KDM4E
SCHEMBL775333 0.77 NPC1 (0.61) MAPTLMNAPDGFRBPDGFRANOTUM
SCHEMBL1743253 0.77 NPC1 (0.52) MAPTLMNANOTUMSMN1; SMN2
SCHEMBL1509577 0.77 SMN1; SMN2 (0.61) MAPTLMNANOTUMPIK3CDPIK3CA
SCHEMBL1742549 0.76 CYP2A6 (0.64) MAPTLMNAPDGFRBPDGFRANOTUM
SCHEMBL6782503 0.76 PDGFRB (0.54) MAPTLMNAPDGFRBPDGFRAKDR
SCHEMBL16161600 0.75 RAB9A (0.58) MAPTLMNAKDM4ESMN1; SMN2
SCHEMBL22377052 0.75 MAPT (0.55) MAPTLMNAPDGFRBPDGFRANOTUM
SCHEMBL12786341 0.75 NPC1 (0.60) MAPTLMNAPDGFRBPDGFRANOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294520-A1 AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE PLIANT THERAPEUTICS INC (US) 2024-09-05 US disclosed
CN-112689507-B Amino acid compounds having unbranched linkers and methods of use thereof 普利安特治疗公司 2024-07-30 CN disclosed
US-11858931-B2 Amino acid compounds with unbranched linkers and methods of use PLIANT THERAPEUTICS, INC. (US) 2024-01-02 US disclosed
US-20220289743-A1 AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE PLIANT THERAPEUTICS, INC. 2022-09-15 US disclosed
US-11396506-B2 Amino acid compounds with unbranched linkers and methods of use PLIANT THERAPEUTICS, INC. (US) 2022-07-26 US disclosed
CN-112689507-A Amino acid compounds having unbranched linkers and methods of use thereof 普利安特治疗公司 2021-04-20 CN disclosed
US-20200123151-A1 AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE PLIANT THERAPEUTICS, INC. 2020-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11396506-B2 Amino acid compounds with unbranched linkers and methods of use ITGA2B, ITGB6, ITGB1 MAPT 3535/4885LMNA 1777/4885PDGFRB 76/4885
US-20200123151-A1 AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE ITGA2B, ITGB6, ITGB1 MAPT 3535/4885LMNA 1777/4885PDGFRB 76/4885
US-20240294520-A1 AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE ITGA2B, ITGB6, ITGB1 MAPT 3535/4885LMNA 1777/4885PDGFRB 76/4885
US-11858931-B2 Amino acid compounds with unbranched linkers and methods of use ITGA2B, ITGB6, ITGB1 MAPT 3535/4885LMNA 1777/4885PDGFRB 76/4885
US-20220289743-A1 AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE ITGA2B, ITGB6, ITGB1 MAPT 3535/4885LMNA 1777/4885PDGFRB 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.